• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=28683746).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=9000147; PubMed=24042735; PubMed=28683746).
  

vitro multistep carcinogenesis model.
Oncogene 10:2145-2153(1995)

assay.
J. Cancer Res. Clin. Oncol. 121:230-234(1995)

Yoshinori S. Murakami, Hans Albertsen, Arthur R. Brothman, Robin Jean Leach, Raymond Leslie White;
Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10.
Cancer Res. 56:2157-2160(1996)

pancreatic carcinomas.
Cancer Res. 56:5360-5364(1996)

upper aero-digestive tract.
Cancer Lett. 118:115-121(1997)

constitutive hypermutation in a Burkitt's lymphoma line.
Oncogene 19:3404-3410(2000)

William George Kaelin Jr., Sabina Signoretti;
Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Cancer Res. 69:4674-4681(2009)

Luca Bologna, Marek Kosinski, David Viertl, Angelika Bischof Delaloye, Christian Berthou, Jean-Pierre Mach, Laurence Boumsell;
Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Mol. Cancer 10:42.1-42.12(2011)

Clin. Cancer Res. 20:5733-5744(2014)

YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity.
Oncogene 37:5492-5507(2018)